Health Secretary Robert F. Kennedy Jr. has unilaterally issued a rule that will let specialty pharmacies sell six specific peptide drugs, overruling scientists at the Food and Drug Administration.
The rule is titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It was made available Wednesday on the Federal Register, with final publication set for October 30. It does not change the regulatory status of the peptides; it states that the Department of Health and Human Services will no longer take enforcement action against compounding pharmacies that make them — effectively a green light to produce and sell.
The six are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. They are popular within Kennedy's Make America Healthy Again movement, and many prominent MAHA figures and Kennedy allies sell them. Kennedy has said he uses some of the peptides and is a "big fan." FDA scientists continue to say there is insufficient evidence of effectiveness and that the drugs are potentially dangerous; in 2023 those safety concerns led the agency to remove the six from the list of substances compounding pharmacies may make in bulk.
How the rationale was built. HHS cites, among other things, a July vote by an FDA advisory panel to add the six peptides back to that list. But before the vote, Kennedy stacked the 12-member committee with eight new members; at least six of his additions have ties to peptide-related businesses and clinics, raising conflict-of-interest concerns. Another argument in the policy is that safety concerns are mainly hypothetical or "inferential" rather than based on observed human harm. That is largely because there are few to no human studies showing either benefits or harms.
Kennedy also argues that wider availability through pharmacies improves safety, by discouraging people from buying peptides on the gray or black market, or buying research-use-only formulas from foreign manufacturers. Compounded peptides are "a more controlled alternative," the HHS document states, and the policy "advances patient choice and freedom while appropriately protecting patient safety."
Why it matters. It is a precedent for how evidence is handled in this administration: a advisory committee is reshuffled, an agency is overruled, and the instrument is not an approval but a promise not to enforce. Sellers celebrated immediately. Brigham Buhler, who sells peptides through a wellness clinic, thanked Kennedy, President Trump, Calley Means and Joe Rogan: "Medical freedom just took a major step forward!" Lee Rosebush, chair of the American Academy of Peptide Medicine, praised a "forward-thinking, evidence-based approach to the regulation of peptides."
Critics pushed back. The Center for Science in the Public Interest warned in advance that reports of harms will mount, and that reputable drugmakers will have less incentive to run thorough trials if a peptide is already widely available. Fred Mills of Americans for Safe and Effective Medicines said the rule "does not resolve problems with untested products, safety risks, questionable ingredients, or misleading claims" and will worsen harms from mass compounding.
One caveat: the rule is not yet finally published, and it bans nothing — it announces non-enforcement. Legal challenges are plausible, and whether pharmacies actually ship depends partly on liability questions the document does not settle.
